FATE · Company research
Fate Therapeutics, Inc. (FATE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside - TradingView | Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside TradingView | View source ↗ | TradingView | Oct 16, 2026 | neutral | 0 | 0.6 |
| Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Singapore | Fate Therapeutics, Inc. (FATE) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 13, 2026 | neutral | 0 | 0.6 |
| Fate Therapeutics Appoints Jamie Harrell to Lead Commercial Strategy as FT819 Advances in Phase 2 Lupus Nephritis Trial - Quiver Quantitative | Fate Therapeutics Appoints Jamie Harrell to Lead Commercial Strategy as FT819 Advances in Phase 2 Lupus Nephritis Trial Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 12, 2026 | neutral | 0 | 0.6 |
| Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. - Stock Titan | Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits | FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Consensus Target Price of $5.90 - MarketBeat | Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Consensus Target Price of $5.90 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus - Stocktwits | S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Fate Therapeutics grants employee awards: what it means for Fate Therapeutics stock - AD HOC NEWS | Fate Therapeutics grants employee awards: what it means for Fate Therapeutics stock AD HOC NEWS | View source ↗ | AD HOC NEWS | Oct 7, 2026 | neutral | 0 | 0.6 |
| Fate Therapeutics (NASDAQ:FATE) Shares Cross Above 50-Day Moving Average - Time to Sell? - MarketBeat | Fate Therapeutics (NASDAQ:FATE) Shares Cross Above 50-Day Moving Average - Time to Sell? MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| 4 Developments That Will Determine the Fate of Lucid and Potential Bankruptcy - The Motley Fool | 4 Developments That Will Determine the Fate of Lucid and Potential Bankruptcy The Motley Fool | View source ↗ | The Motley Fool | Oct 3, 2026 | neutral | 0 | 0.6 |
| Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Australia | Fate Therapeutics, Inc. (FATE) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 2, 2026 | neutral | 0 | 0.6 |
| Two new hires at Fate Therapeutics get stock awards that vest over four years if they stay - Stock Titan | Two new hires at Fate Therapeutics get stock awards that vest over four years if they stay Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences | Fate Therapeutics announced that management will participate in two major investor conferences in Q4 2026: the Jefferies Global Healthcare Conference in London (November 16-19) and the Piper Sandler 38th Annual Healthcare Conference in New York (December 1-3). Live webcasts will be available on the company's investor website. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | neutral | 0 | 1 |
| Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative | Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 25, 2026 | neutral | 0 | 0.6 |
| Dan Sullivan’s wife enters political fray to attack Mary Peltola - Newsweek | Dan Sullivan’s wife enters political fray to attack Mary Peltola Newsweek | View source ↗ | Newsweek | Sep 23, 2026 | neutral | 0 | 0.6 |
| H.C. Wainwright reiterates Fate Therapeutics stock rating at buy - Investing.com | H.C. Wainwright reiterates Fate Therapeutics stock rating at buy Investing.com | View source ↗ | Investing.com | Jul 10, 2026 | neutral | 0 | 0.6 |
| Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade | Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders StocksToTrade | View source ↗ | StocksToTrade | Jun 28, 2026 | neutral | 0 | 0.6 |
| $FATE stock is up 11% today. Here's what we see in our data. - Quiver Quantitative | $FATE stock is up 11% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | May 21, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.